zurück Home

Primärtherapie des Mamma - Karzinoms

allgemeines

Mamma-Ca Therapie

Diagnose-Sicherung

Ausbreitungs-Diagnostik

Sondersituationen

operative Therapie

praeoperative Therapie

postoperative Bestrahlung

adjuvante systemische Therapie

brusterhaltende Therapie

HER2 + Rezeptor +

ALTERNATIVE-Studie Lapatinib + Trastzumab + Aromatasehemmer (doppelte Her2-Blockade) besser als Trastzumab + Aromatasehemmer oder Lapatinib + Aromatasehemmer
Quellen 1.) Early Breast Cancer Trialists' Collaborative Group (EBCTCG)Darby S, McGale P, et al.:
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
Lancet 2011;378:1707–1716

2.) Johnston S R D, et al.:
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor – Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.
J Clin Oncol 2020;39:79-89
DOI org/10.1200/JCO.20.01894

Teil von

Therapie des Mamma - Karzinoms Mamma - Karzinom

blauer Punkt

Impressum                             Zuletzt geändert am 31.01.2020 11:56